Current markers of early neurodegeneration include β-amyloid plaque accumulation and Tau-mediated neuronal injury; both of which are thought to emerge prior to significant cognitive deficits and measurable brain atrophy. Unfortunately, the role of these biomarkers within the cascade of pathophysiological processes of AD remains poorly understood. Impairment in the glymphatic clearance system has garnered attention and is thought to represent a pathway to decline. Here we demonstrate that quantification of glymphatic clearance measures are feasible in healthy controls. Combining these measures with cognitive performance scores and diagnosis will provide insight into the role of the glymphatics system with decline.
This abstract and the presentation materials are available to members only; a login is required.